Base-modified ribonucleosides as potential anti-hepatitis C virus agents.

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• Hepatitis C virus (HCV) infection is a global health concern requiring effective antiviral therapies.
• Development of novel nucleoside analogues is a promising strategy for HCV treatment.
• Targeting viral enzymes like RNA-dependent RNA polymerase (RdRp) and helicase (NS3) is crucial for inhibiting viral replication.

Purpose of the Study:

• To synthesize and evaluate novel base-modified ribonucleoside analogues as potential anti-HCV agents.
• To investigate the activity of these analogues against HCV replication.
• To explore the potential of bicyclic pyrimidine ribonucleoside triphosphates as inhibitors of HCV RdRp (NS5B) and NS3 proteins.

Main Methods:

• Synthesis of four novel series of base-modified ribonucleoside analogues.
• In vitro evaluation of synthesized compounds for anti-HCV activity.
• Biochemical assays to study the interaction of nucleoside triphosphates with HCV NS5B and NS3 proteins.

Main Results:

• Two synthesized compounds exhibited notable anti-HCV activity.
• The triphosphates of bicyclic pyrimidine ribonucleosides were identified as substrates/inhibitors.
• These compounds target essential HCV enzymes, including RNA-dependent RNA polymerase (NS5B) and RNA helicase/NTPase (NS3).

Conclusions:

• Novel base-modified ribonucleoside analogues show promise as anti-HCV therapeutics.
• Specific compounds demonstrate significant antiviral effects by inhibiting key viral enzymes.
• Further development of these analogues could lead to new treatments for Hepatitis C virus infection.